An expert is one who knows more and more about less and less until he knows absolutely everything about nothing

Showing posts with label FDA approval. Show all posts
Showing posts with label FDA approval. Show all posts

Friday, March 18, 2016

FDA Approves Daklinza



Daklinza (daclatasvir) Tablets

Company: Bristol-Myers Squibb Company
Date of Approval: July 24, 2015
Treatment for: Chronic Hepatitis C
Daklinza in combination with sofosbuvir is the first 12-week, once-daily, all-oral treatment regimen for patients with chronic hepatitis C virus (HCV) genotype 3.
The U.S. Food and Drug Administration (FDA) has approved Daklinza (daclatasvir), an NS5A replication complex inhibitor indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection.
PATIENT INFORMATION
Read this Patient Information before you start treatment and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.
IMPORTANT INFORMATION
Daklinza is used in combination with the antiviral medicine sofosbuvir (Sovaldi).
You should not take Daklinza alone to treat chronic hepatitis C infection.
You should also read the Patient Information for sofosbuvir (Sovaldi).
WHAT IS DAKLINZA?
  • Daklinza is a prescription medicine used with sofosbuvir to treat chronic (lasting a long time) hepatitis C genotype 3 infection in adults.
  • Daklinza should not be taken alone.
It is not known if this medicine is safe and effective in children under 18 years of age.
BEFORE TAKING DAKLINZA
Before taking Daklinza, tell your healthcare provider about all of your medical conditions, including if you:
  • have liver problems other than hepatitis C infection
  • have had a liver transplant
  • have heart problems
  • are pregnant or plan to become pregnant. It is not known if this medicine will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if this medicine passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Daklinza may affect the way other medicines work, and vice versa, which may cause side effects.
Keep a list of your medicines to show your healthcare provider and pharmacist.
  • You can ask your healthcare provider or pharmacist for a list of medicines that interact with Daklinza.
  • Do not start taking a new medicine without telling your healthcare provider. Your healthcare provider can tell you if it is safe to take Daklinza with other medicines.
HOW SHOULD I TAKE DAKLINZA?
  • Take Daklinza exactly as your healthcare provider tells you to.
  • Do not change your dose unless your healthcare provider tells you to.
  • Do not stop treatment without first talking with your healthcare provider.
  • Take Daklinza one time each day with or without food.
  • If you miss a dose, take the missed dose as soon as you remember the same day. Take the next dose at your regular time.
  • If you miss a dose and remember the next day, skip the missed dose. Take the next dose at your regular time.
  • Do not take two doses at the same time to make up for the missed dose.
  • If you exceed your prescribed dose, call your healthcare provider or go to the nearest hospital emergency room right away.

DAKLINZA SIDE EFFECTS
Daklinza in combination with sofosbuvir and amiodarone may cause serious side effects, including:
  • Slow heart rate (bradycardia). Daklinza combination treatment with sofosbuvir may result in slowing of the heart rate (pulse) along with other symptoms when taken with amiodarone, a medicine used to treat certain heart problems. Get medical help right away if you take amiodarone with sofosbuvir and Daklinza and get any of the following symptoms:
    • fainting or near-fainting
    • weakness
    • chest pain
    • dizziness or lightheadedness
    • tiredness
    • confusion
    • not feeling well
    • shortness of breath
    • memory problems
The most common side effects of Daklinza when used in combination with sofosbuvir include:
  • headache
  • tiredness
These are not all the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
HOW SHOULD I STORE DAKLINZA?
  • Store Daklinza at room temperature between 68°F and 77°F (20°C and 25°C).
Keep all medicines out of the reach of children.
GENERAL INFORMATION ABOUT THE SAFE AND EFFECTIVE USE OF DAKLINZA
It is not known if treatment with Daklinza will prevent you from infecting another person with the hepatitis C virus during treatment. Talk with your healthcare provider about ways to prevent spreading the hepatitis C virus.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use this medicine for a condition for which it was not prescribed. Do not give it to other people, even if they have the same symptoms that you have. It may harm them.
You can ask your pharmacist or healthcare provider for information that is written for health professionals.
WHAT ARE THE INGREDIENTS IN DAKLINZA?
Active ingredient: daclatasvir
Inactive ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, silicon dioxide, magnesium stearate, and Opadry green. Opadry green contains hypromellose, titanium dioxide, polyethylene glycol 400, FD&C blue #2/indigo carmine aluminum lake, and yellow iron oxide.

New Drug Approval Process



FDA Approvals

It takes on average 12 years and over US$350 million to get a new drug from the laboratory onto the pharmacy shelf. Once a company develops a drug, it undergoes around three and a half years of laboratory testing, before an application is made to the U.S. Food and Drug Administration (FDA) to begin testing the drug in humans. Only one in 1000 of the compounds that enter laboratory testing will ever make it to human testing.

If the FDA gives the green light, the “investigative” drug will then enter three phases of clinical trials:
  • Phase 1 uses 20-80 healthy volunteers to establish a drug’s safety and profile. (about 1 year)
  • Phase 2 employs 100-300 patient volunteers to assess the drug’s effectiveness. (about 2 years)
  • Phase 3 involves 1000-3000 patients in clinics and hospitals who are monitored carefully to determine effectiveness and identify adverse reactions. (about 3 years)
The company then submits an application (usually about 100,000 pages) to the FDA for approval, a process that can take up to two and a half years. After final approval, the drug becomes available for physicians to prescribe. At this stage, the drug company will continue to report cases of adverse reactions and other clinical data to the FDA.
The research-based pharmaceutical industry currently invests some US$12.6 billion a year in new drug development. Historically, the drug development figure doubles every five years.
Steps from Test Tube to New Drug Application Review

FDA Takes Action Against Unapproved Prescription Ear Drop Products



July 1, 2015
The U.S Food and Drug Administration today announced its intention to take enforcement action against companies that manufacture and/or distribute certain unapproved prescription ear drop products (known as otic products) labeled to relieve ear pain, infection, and inflammation.
The unapproved prescription ear drops contain active ingredients such as benzocaine and hydrocortisone, and have not been evaluated by the FDA for safety, effectiveness and quality. The labels on these products do not disclose that they lack FDA approval, and health care professionals may not be aware of their unapproved status.
In a federal register notice published today, the agency informed the companies that they must stop manufacturing these unapproved prescription otic products or be subject to enforcement actions, including seizure, injunction and/or criminal proceedings. Today’s action does not affect FDA-approved prescription otic products, or legally marketed otic products sold over-the-counter.
Unapproved prescription otic drug products containing the following ingredients are covered by this action:
  • benzocaine
  • benzocaine and antipyrine;
  • benzocaine, antipyrine, and zinc acetate;
  • benzocaine, chloroxylenol, and hydrocortisone;
  • chloroxylenol and pramoxine; and
  • chloroxylenol, pramoxine, and hydrocortisone.
“Taking enforcement actions against these unapproved products will protect patients from unnecessary risks,” said Cynthia Schnedar, director of the Office of Compliance in the FDA’s Center for Drug Evaluation and Research. “There are many FDA-approved prescription products to treat ear infections, so we expect little or no impact on patients from the removal of these unapproved and potentially unsafe products.”
Unapproved prescription otic drug products are frequently given to young children suffering from ear infections and other conditions that cause ear pain and swelling. Patients taking unapproved drugs may be at greater risk because there is no proven safety or effectiveness information. These products may be contaminated or manufactured incorrectly, which could result in patients receiving the wrong dose, even when administered according to the labeled directions for use.
Companies making and selling unapproved otic drug products covered by this action that are not currently listed with the FDA must stop manufacturing and shipping the products immediately. Companies that wish to market the drug products covered by this action can submit a new drug application (NDA) or an abbreviated new drug application (ANDA) for the FDA to consider approval of these products.
Consumers who believe they are using unapproved prescription ear drops should contact their health care provider to discuss alternatives. Today’s action is part of the FDA’s Unapproved Drugs Initiative, which seeks to reduce consumer exposure to drugs that are not proven to be safe, effective and of high quality.
Consumers and health care professionals are encouraged to report adverse events or medication errors from the use of unapproved prescription products to the FDA’s MedWatch Adverse Event Reporting Program.


Source: FDA

FDA approves brain implant to help reduce Parkinson’s disease and essential tremor symptoms


 U.S. Food and Drug Administration today approved the Brio Neurostimulation System, an implantable deep brain stimulation device to help reduce the symptoms of Parkinson’s disease and essential tremor, a movement disorder that is one of the most common causes of tremors. The Brio Neurostimulation System can help some patients when medication alone may not provide adequate relief from symptoms such as walking difficulties, balance problems, and tremors.An estimated 50,000 Americans are diagnosed with Parkinson’s disease each year, according to the National Institutes of Health, and about one million Americans have the condition. The neurological disorder typically occurs in people over age 60, when cells in the brain that produce a chemical called dopamine become impaired or die. Dopamine helps transmit signals between the areas of the brain that produce smooth, purposeful movement — like eating, writing and shaving.

Essential tremor affects several million people and usually occurs in those over age 40. “There are no cures for Parkinson’s disease or essential tremor, but finding better ways to manage symptoms is essential for patients,” said William Maisel, M.D., M.P.H., acting director of the Office of Device Evaluation at the FDA’s Center for Devices and Radiological Health. “This new device adds to the array of treatment options to help people living with Parkinson’s and essential tremor enjoy better, more productive lives.”The Brio Neurostimulation System consists of a small (1.9in x 2.1in x 0.4in) battery-powered, rechargeable electrical pulse generator implanted under the skin of the upper chest and wire leads that attach to electrodes placed within the brain at specific locations depending on whether the device is being used to treat Parkinson’s disease or essential tremor. The electrical pulse generator continuously delivers low intensity electrical pulses to target areas in the brain. Health care providers make adjustments to the pulse generator to optimize the effects of the Brio Neurostimulation System.
Data supporting the safety and effectiveness of the device system included two clinical studies. One study included 136 patients with Parkinson’s disease and the other included 127 patients with essential tremor. In both studies, patients had symptoms, including tremors, that were not adequately controlled with drug therapy.The Brio Neurostimulation System was used in addition to medication for patients with Parkinson’s disease and the majority of patients with essential tremor who used the device were able to control their symptoms without the need for medications. Researchers implanted the Brio Neurostimulation System in all patients and assessed effectiveness for Parkinson’s disease patients at three months and essential tremor patients at six months. Both groups showed statistically significant improvement on their primary effectiveness endpoint when the device was turned on compared to when it was turned off.
Serious adverse events included intracranial bleeding, which can lead to stroke, paralysis or death. Other device-related adverse events included infection and dislocation of the device lead under the skin. The Brio Neurostimulation System is manufactured by St. Jude Medical in St. Paul, Minnesota.
Brio Neurostimulation System is the second device approved by the FDA for Parkinson’s and essential tremor. The first device, Medtronic’s Activa Deep Brain Stimulation Therapy System, was approved in 1997 for tremor associated with essential tremor and Parkinson’s disease. In 2002, the indications were expanded to include the symptoms of Parkinson’s disease.In its early stages, Parkinson’s disease typically affects one side of the body and starts as problems with movement, stiffness, and mild tremors. Gradually, the symptoms can affect both sides of the body and medications may become less effective. People with late stage Parkinson’s disease have many symptoms including: trouble walking, impaired posture and balance, muscle stiffness and tremors in the arms and hands that make it difficult to perform everyday tasks.
Essential tremor most often affects the hands and arms and can be slowly progressive, starting on one side of the body but eventually affecting both sides. Hand tremor is the most common symptom, but tremors can also affect movement in the head, arms, voice, tongue, legs, and trunk. About half of essential tremor cases result from a genetic mutation. For the remainder of cases, the cause is unknown.

Drug Shortages: Has the FDA Response Made an Impact?


Rationing of much needed medications for patients is a scary thought for me as a healthcare professional. I can understand when an orphan drug may go in short supply for a rare disease, but when commonly used medications like antibiotics and intravenous fluids become scarce, I wonder what the forces are that cause this to happen, and why can’t it be prevented? Worse yet, how could a patient even begin to understand or combat such a specific ordeal?
Drug shortages in the U.S. continue to occupy headline news. In some instances, the shortages are for commonplace treatments like intravenous (IV) normal saline solutions, IV nitroglycerin, anesthesia drugs, IV multivitamins, and antibiotics. Other drugs in short supply have included life-saving cancer medicines, and treatments for tuberculosis, Lyme disease, and ADHD. Take note: these are not orphan drugs or orphan diseases, but everyday treatments used for common ailments.
Why are there drug shortages?
There is no one easy answer to this question. First, it’s important to understand how a drug shortage is defined. According to FDA, “a shortage is considered to be the period of time when the demand for the drug within the U.S. exceeds the supply of the drug.” For the FDA, identified drug shortages would involve medically necessary products that have a significant effect on public health. A medically necessary drug is used to treat or prevent a serious disease or medical condition and for which no acceptable drug alternative is available in adequate supply. However, the agency does consider all possible drug shortages to determine if they are medically necessary. The American Society of Health-System Pharmacists (ASHP) considers a drug product to be in a shortage once it is verified with manufacturers, regardless of whether the product is or is not medically necessary.
The reasons behind drug shortages are as varied as the drugs themselves. Top reasons include:
  • Quality: manufacturing delays or quality issues.
  • Raw materials may be in short supply.
  • Demand for the drug may increase.
  • Loss of drug manufacturing site or production line.
  • Drug discontinuation or lack of financial incentive.
The manufacturing process for pharmaceutical agents, especially sterile IV products can be especially complicated and may involve many steps. According to a recent infographic supplied by FDA, quality issues are the top reason for lack of treatment and affect 67% of all drug shortages. Twenty-seven percent of the time raw material may simply not be available. An uptick in public demand can also result in drug shortages, as has occurred in the past with flu vaccines and antiviral treatments.
Drug discontinuation and lack of financial incentive is especially concerning. While the FDA has the authority to seek alternative sources for a needed drug in short supply, FDA cannot force a manufacturer to supply a drug it decides to discontinue. It is costly for a manufacturer to research, develop, and market a drug that is not in high demand, especially if it is a generic product or an older sterile injectable medication. The company may make a business decision that older drugs should be removed from their portfolio in favor of newly-branded and more profitable medications.
What are the impacts of drug shortages?
Patient safety issues for drug shortages can be immense. Besides the lack of effective drug treatment, other areas of medical care that are impacted include:
  • Medical procedure and drug treatment protocol delays.
  • Higher rates of relapse among patients with cancer or other chronic disease.
  • Elevated rates of medication errors, possibly due to lack of study data on drug substitutes.
  • Ethical questions or bias when determining how to distribute drugs in short supply.
  • Healthcare providers may not have experience with dosing or preparation of required therapeutic alternatives.
  • Reduced patient health outcomes.
  • Spikes in drug procurement cost.
  • Patients may decide to purchase needed drugs online or from foreign countries.
A survey conducted with pharmacists by The Institute for Safe Medication Practices (ISMP) in 2012 revealed medications most commonly involved in side effects due to drug shortages:
  • Chemotherapy (27%), particularly doxorubicin.
  • Opioid analgesics (17%), mostly fentanyl and morphine
  • Electrolytes (7%)
  • Antibiotics (5%)
  • Phentolamine (4%)
  • Phytonadione (4%)
However, the FDA has implemented legal regulations with manufacturers to curtail these impacts. Title X of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 now requires all drug makers to give advanced notice to the FDA about impending critical drug discontinuations (at least 6 months in advance) or production interruptions (as soon as possible). This allows the FDA to work with the manufacturers to help prevent unknown, possible life-threatening drug shortages. As noted by ASHP this includes drugs that are:
  • Life-supporting or life-sustaining
  • Use to prevent or treat a debilitating disease or condition
  • Used in emergency medical care or during surgery
The FDA may also quicken the review of a manufacturer’s new drug application in order to mitigate possible shortages. To enforce the new law, the FDA follows up with the manufacturer in the case of noncompliance and the manufacturer must reply within 30 days. In addition, the FDA must give an annual report to Congress on drug shortages, outlining manufacturers who do not notify of impending shortages, plus any FDA actions taken to lessen drug shortages, coordination with the DEA, and other measures.
Manufacturers are required to report drug discontinuances to FDA regardless of whether they intend to remove the product from the market permanently or only have an interruption of supply. However, FDA encourages firms to notify them of any potential supply issues at any point in the manufacturing process. The FDA is now required to maintain an up-to-date list of drugs in short supply. ASHP also maintains a more inclusive list of drug shortages.
Case examples
  • IV sodium chloride (saline)
A shortage of 0.9% sodium chloride solution used to replace electrolytes or administer medications has taken a toll since increase demand started in the 2013-2014 flu season. Normal saline, a dilute salt and water solution, is used frequently in hospitals and clinics for irrigating wounds, rehydrating patients, and serving as a diluent for IV medications like chemotherapy and antibiotics, among many other uses. According to Baxter, a top supplier, over 740 units of saline and other sterile solution are used every 60 seconds across the United States. Shortages of normal saline have resulted in pharmacists and nurses having to limit their use of the IV solution and creating workarounds to ensure ample supply. Currently, the most affected product is the 1,000 milliliter bag of sodium chloride.
FDA has intervened to help address the normal saline shortage. Alternate sources of normal saline were identified from oversea suppliers. FDA is also working with other American manufacturers, including Baxter Healthcare Corp., Fresenius Kabi USA, LLC., and Hospira Inc., to restore an adequate supply of normal saline for U.S. hospitals and health clinics.
  • Antibiotics and Anti-Infectives
Shortages of antibiotics in the U.S. are an ongoing concern. In fact, according to experts, antibiotics are being removed from the market six times faster than new ones are being produced. Between 2001 and 2013, there were shortages of 148 antibiotics. This is of great concern to the FDA and the healthcare community as many of these antibiotics are the sole drugs to treat certain antibiotic-resistant infections or for certain pediatric infectious diseases. Another concern: many of these life-threatening infections picked up from a hospital (nosocomial infection) or outpatient surgical clinic require these last-line medications.
In a 2015 study done at George Washington University, nearly half the shortages were for antibiotics needed to treat severe and resistant infections, including:
  • Clostridium difficille
  • Carbapenem-resistant Enterobacteriaceae (CRE)
  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • Pseudomonas aeruginosa
Even more common drugs, like aztreonam used to treat serious infections in patients allergic to penicillin, and trimethoprim/sulfamethoxazole, used to treat pneumocystis pneumonia, were in short supply with no alternate manufacturers.
What has the response been to the new regulations?
FDA has made a significant impact on drug shortages. FDA address shortages by:
  • Working with firms to resolve manufacturing issues to allow medications to return to the market.
  • Speeding up FDA’s review process so that new manufacturers can supply needed products as soon as possible.
  • Helping firms get new sources of raw material.
  • Expediting review of pharmaceutical manufacturing lines.
  • Extend expiration dates if data can confirm safety and effectiveness.
  • Procuring critical drugs from foreign manufacturing plants that meet FDA quality standards.
  • Development of a long-term strategic action that manufacturers can take to help prevent future shortages.
According to the FDA, drug shortages peaked in 2011 with 251 shortages. Up until that time shortages had been steadily increasing since 2006 when there were 56 reported shortages. However, in 2013 and 2014, there were only 44 newly reported drug shortages in each year, the lowest in over a decade. Most importantly, in the time between 2011 to 2013, FDA was able to help avert over 740 drug shortages. The new regulations requiring early notification from drug manufacturers have been able to positively impact these numbers.
Healthcare systems, including hospitals and pharmacy benefit managers (PBMs) are also addressing drug shortages by developing their own internal protocols, ethical standards, and review process to combat drug shortages.
What actions should a patient take?
  • If you have a concern that a drug you or a family member requires may be in short supply, talk with your doctor. There may be alternatives available.
  • Ask your healthcare provider or insurance if their associated hospitals or organizations, such as Pharmacy Benefit Managers (PBMs), have a policy in place for drug shortage management.
  • Do not buy substitute medications on the Internet or from a foreign country due to lack of quality assurance, potential fraud, and risk for toxicity.
  • Visit the Drugs.com Current U.S. Drug Shortages page to see if a drug you are questioning is listed.
  • If your drug is not on the list, email the name and dose of the drug, along with your contact information to the FDA at: drugshortages@fda.hhs.gov.


FDA Approves Addyi


Addyi (flibanserin) Tablets
Company: Sprout Pharmaceuticals, Inc.
Date of Approval: August 18, 2015
Treatment for: Hypoactive Sexual Desire Disorder
Addyi is the first and only FDA-approved treatment for hypoactive sexual desire disorder, the most common form of female sexual dysfunction.The U.S. FDA has approved Addyi (flibanserin), a once-daily, non-hormonal, multifunctional serotonin agonist antagonist (MSAA) for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
MEDICATION GUIDE
Read this Medication Guide before you start treatment and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor.
IMPORTANT INFORMATION
Your risk of severe low blood pressure and fainting (loss of consciousness) is increased if you take Addyi and:
  • drink alcohol. Do not drink alcohol if you take Addyi.
  • take certain prescription medicines, over-the-counter medicines, or herbal supplements. Do not take or start taking any prescription medicines, over-the-counter medicines, or herbal supplements during treatment until you have talked with your doctor. Your doctor will tell you if it is safe to do so.
  • have liver problems. Do not take Addyi if you have liver problems.
If you feel lightheaded or dizzy during treatment, lie down right away. Get emergency medical help or ask someone to get emergency medical help for you if the symptoms do not go away or if you faint (lose consciousness). If you faint, tell your doctor as soon as you can.
Addyi is only available through the Addyi risk evaluation and mitigation strategy (REMS) Program because of the increased risk of severe low blood pressure and fainting with alcohol use. You can only get Addyi from pharmacies that are enrolled in the Addyi REMS Program. For more information about the Program and a list of pharmacies that are enrolled in the Addyi REMS Program, go to www.AddyiREMS.com or call 1-844-PINK-PILL (1-844-746-5745).
WHAT IS ADDYI?
Addyi is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women who have not gone through menopause, who have not had problems with low sexual desire in the past, and who have low sexual desire no matter the type of sexual activity, the situation, or the sexual partner. Women with HSDD have low sexual desire that is troubling to them. Their low sexual desire is not due to:
  • a medical or mental health problem
  • problems in the relationship
  • medicine or other drug use
It is is not for use for the treatment of HSDD in women who have gone through menopause, or in men.
Addyi is not for:
  • use to improve sexual performance
  • use in children
WHO SHOULD NOT TAKE ADDYI?
Do not take Addyi if you:
  • drink alcohol
  • take certain other medicines. Taking Addyi with certain other medicines can increase the amount of Addyi in your blood and cause severe low blood pressure, fainting, and sleepiness. Do not take Addyi if you are taking any of the following medicines:
    • certain medicines used to treat HIV-1 infection, such as:
      • amprenavir
      • atazanavir (Reyataz)
      • fosamprenavir (Lexiva)
      • ritonavir (Norvir)
      • saquinavir (Invirase)
      • nelfinavir (Viracept)
      • indinavir (Crixivan)
    • certain medicines that you take by mouth used to treat fungal infections, such as:
      • fluconazole (Diflucan)
      • ketoconazole
      • itraconazole (Onmel, Sporanox)
      • posaconazole (Noxafil)
    • certain antibiotics, including:
      • ciprofloxacin (Cipro, Cipro XR)
      • erythromycin (Ery-Tab, Eryc,PCE)
      • telithromycin (Ketek)
      • clarithromycin (Biaxin)
    • certain medicines used to treat Hepatitis C infection, such as:
      • boceprevir (Victrelis)
      • telaprevir
    • certain medicines used to treat high blood pressure, chest pain (angina), or other heart problems, such as:
      • diltiazem (Cardizem, Cardizem CD, Cardizem LA, Cartia XT, Dilt CD, Diltzac, Taztia XT, Tiazac)
      • verapamil (Calan, Calan SR, Covera-HS, Verelan, Verelan PM)
      • conivaptan (Vaprisol)
    • nefazodone: a medicine used to treat depression
    Ask your doctor or pharmacist if you are not sure if you take any of the medicines listed above. These are examples of the medicines that you should not take if you are taking Addyi. Tell your doctor about all of the medicines you take before you start treatment.
  • have liver problems
BEFORE TAKING ADDYI
Before you take Addyi, tell your doctor about all of your medical conditions, including if you:
  • drink alcohol, use drugs or have a history of alcohol or drug abuse
  • have ever had depression or other mental health problems
  • have low blood pressure or a medical condition that can cause low blood pressure
  • are pregnant or plan to become pregnant. It is not known if Addyi will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if Addyi passes into your breast milk. You and your doctor should decide if you will take Addyi or breastfeed. You should not do both.
Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Addyi can affect the way other medicines work and vice versa, and can cause serious side effects.
Know the medicines and herbal supplements you take. Keep a list of them to show your doctor or pharmacist each time you get a new medicine.
HOW SHOULD I TAKE ADDYI?
  • Take Addyi exactly as your doctor tells you to take it.
  • Take one tablet once a day at bedtime. Taking the tablet at a time other than bedtime can increase your risk of low blood pressure, fainting, accidental injury, and sleepiness.
  • If you miss a dose, skip your missed dose. Take your next dose at bedtime the next day.
  • Do not take Addyi the next morning or double your next dose. If you overdose, call your doctor.
  • Tell your doctor if your symptoms of HSDD have not improved after you have taken Addyi for 8 weeks.
WHAT SHOULD I AVOID WHILE TAKING ADDYI?
  • Do not drive, operate machinery, or do things that require clear thinking until at least 6 hours after you take Addyi and until you know how Addyi affects you.
  • Do not drink grapefruit juice. Drinking grapefruit juice during treatment increases your risk of severe low blood pressure and fainting.
  • You should not take the herbal supplements St. John’s Wort, ginkgo, or resveratrol or certain over-the-counter medicines such as cimetidine until you talk to your doctor. Taking Addyi with these herbal supplements and over-the-counter medicine may increase your risk of low blood pressure, fainting, and sleepiness.
ADDYI SIDE EFFECTS
Addyi can cause serious side effects, including:
  • See Important information
  • Sleepiness is a common side effect and can be serious. Taking Addyi can increase your risk of sleepiness if taken during waking hours, if you drink alcohol, or take certain medicines or herbal supplements.
  • Low blood pressure and fainting can happen during treatment even if you do not drink alcohol or take other medicines or herbal supplements. Your risk of low blood pressure and fainting is increased if Addyi is taken during waking hours, if you drink alcohol, or if you take certain medicines or herbal supplements.
The most common side effects include:
  • dizziness
  • nausea
  • tiredness
  • difficulty falling asleep or staying asleep
  • dry mouth
These are not all of the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
HOW SHOULD I STORE ADDYI?
  • Store the tablets at room temperature between 68°F to 77°F (20°C to 25°C).
Keep all medicines out of the reach of children.
GENERAL INFORMATION ABOUT THE SAFE AND EFFECTIVE USE OF ADDYI
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use this medicine for a condition for which it was not prescribed. Do not give it to other people, even if they have the same symptoms that you have. It may harm them. You can ask your doctor or pharmacist for information that is written for health professionals.
WHAT ARE THE INGREDIENTS IN ADDYI?
Active ingredient: flibanserin
Inactive ingredients: lactose monohydrate, microcrystalline cellulose, hypromellose, croscarmellose sodium, magnesium stearate, talc, macrogol, and the coloring agents, titanium dioxide and iron oxide.

About Blogger:

Hi,I,m Basim from Canada I,m physician and I,m interested in clinical research feild and web development.you are more welcome in our professional website.all contact forwarded to basimibrahim772@yahoo.com.


Let's Get Connected: Twitter | Facebook | Google Plus| linkedin

 

Subscribe to us